Skip to main content

COVID-19 Topic Center

CAR-T Therapies News

News
Chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD30 molecule promoted a durable remission in a 69-year-old man with multiply relapsed enteropathy-associated T-cell lymphoma after previous allogeneic stem cell transplantation. Clinicians described the case in a report published in…
News
Criteria for inclusion and exclusion in clinical trials of chimeric antigen receptor T-cell (CAR‐T) therapy for hematologic malignancies are highly variable and bring to light the need for a more standardized approach to patient enrollment, according to a study published online in the Journal of…
News
Both the United States and Europe approved commercial chimeric antigen receptor T-cell (CAR‐T) therapy products after their striking performance in patients with hematological malignancies in clinical trials, but CAR-T therapy has a dark side, according to a review paper in Critical Reviews in…
News
Although chimeric antigen receptor T‐cell (CAR‐T) therapy has not garnered the same success with solid tumors, including brain tumors, that it has had with hematological malignancies, current strategies to improve effector function of CAR-T therapy provide hope, researchers wrote in a review paper…
News
Feedback from facilities in the United States currently providing inpatient chimeric antigen receptor T‐cell (CAR‐T) therapy about the financial viability of the treatment warrant concern, warns a survey-based study published in published in The Oncologist.  “Reimbursement has been slow, and in…
News
In a recent study, researchers examined the outcomes of patients with chronic lymphocytic leukemia (CLL) treated with CD19-specific Chimeric antigen receptor T-cell (CAR-T) therapy—specifically focusing on overall survival and progression following CART-T treatment. "This data sets a benchmark for…
Conference Insider
Results from an analysis presented at the 2019 ASH Annual Meeting reveal significant risk factors for worse treatment response after CD-19 chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). “[CAR] T-cell therapy targeting CD19…
News
Treatment consisting of CD19-specific chimeric antigen receptor (CAR) T-cell therapy and concurrent ibrutinib demonstrated improved outcomes and fewer severe adverse events in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), revealing the potential benefit of using ibrutinib…
News
CAR-T therapy, a cancer treatment that uses a patient’s own genetically-modified immune cells to fight the disease, will now be covered nationwide by Medicare according to a final decision released by the Centers for Medicare & Medicaid Services, Trump administration, and US Secretary of Health…
Conference Insider
Despite their high price tag, CAR-T regimens were found to be cost-effective compared with other recently approved novel anticancer regimens, according to recent research presented at AMCP Nexus 2018.  For CAR-T therapies approved by the FDA in 2017—each demonstrating promising long-term outcomes—…
Back to Top